Which Medical Device Changes Need Prior Regulatory Approval Under CDSCO Guidelines?

Medical devices undergo continuous improvements throughout their lifecycle, whether to enhance product performance, improve manufacturing efficiency, introduce new technology, or address changing clinical requirements. However, not every modification can be implemented independently by a manufacturer or importer.

In India, medical device modifications are regulated under the Medical Devices Rules (MDR), 2017, administered by the Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare.

A change to an already approved or licensed medical device may require prior regulatory approval, notification to the Licensing Authority, or appropriate supporting documentation, depending on its nature and potential impact on product quality, safety, performance, and intended use.

The Sixth Schedule of the Medical Devices Rules, 2017, specifically categorises post-approval changes into major and minor changes.

Understanding this distinction is essential for manufacturers, importers, authorised agents, and regulatory affairs professionals to avoid non-compliance and ensure uninterrupted product supply.

1. Understanding Post-Approval Changes Under CDSCO

A post-approval change refers to any modification made to a medical device, its manufacturing process, packaging, labelling, or manufacturing site after the relevant regulatory licence or approval has been granted.

Under the Sixth Schedule of MDR, 2017, these modifications are classified into two categories:

• Major changes: Require prior approval from the concerned Licensing Authority before implementation.
• Minor changes: Require notification to the concerned Licensing Authority, as applicable, rather than prior approval under the major-change pathway.

The classification depends primarily on whether the proposed modification could affect the device's quality, safety, performance, stability, or approved intended use.

Importantly, manufacturers should not assume that a modification is minor simply because it appears technically insignificant. Its actual impact on the approved device must be evaluated and documented.

2. Which Medical Device Changes Require Prior Regulatory Approval?

According to the Sixth Schedule of MDR, 2017, the following changes are considered major changes and require prior approval from the applicable Licensing Authority (CLA or SLA), as relevant.

2.1 Change in Material of Construction

Any modification to the material used in manufacturing a medical device may require prior approval if it falls within the major-change category.

Examples include:

• Replacing stainless steel with another material in a surgical instrument.
• Changing the polymer used in a catheter or tubing.
• Modifying the coating of an implant.
• Changing materials that come into contact with patients or biological fluids.

Why is approval important?

A change in material may influence biocompatibility, mechanical strength, durability, chemical stability, and overall product safety. Manufacturers should evaluate these risks and provide relevant supporting evidence.

2.2 Changes in Device Design Affecting Quality or Performance

Design modifications that affect product specifications, indications for use, performance, or stability are considered major changes.

Examples include:

• Modifying the structural design of an implant.
• Changing the dimensions of a critical component where performance is affected.
• Modifying the functional design of a diagnostic instrument.
• Introducing a new design feature that changes device performance.

A design modification that does not affect the specified quality, intended indications, performance, or stability may qualify as a minor change. The classification must be supported by a documented assessment.

2.3 Changes in Intended Use or Indications for Use

A change in the approved intended purpose or clinical indications of a medical device is a major regulatory change.

Examples include:

• Expanding the approved patient population.
• Introducing an additional clinical indication.
• Changing a device from one diagnostic application to another.
• Extending the approved use of a device to a different medical condition.
• Adding a new therapeutic application.

For example, if a diagnostic device is approved for detecting one particular medical condition and the manufacturer intends to introduce an additional diagnostic claim, the proposed modification requires regulatory assessment and prior approval.

CDSCO's IVD FAQs specifically confirm that expanding or modifying approved indications or intended use is a major change requiring prior approval.

2.4 Change in Sterilisation Method

A modification to the approved sterilisation method is considered a major change.

Examples include:

• Changing from ethylene oxide (EtO) sterilisation to gamma radiation.
• Switching from gamma radiation to electron-beam sterilisation.
• Changing the approved sterilisation process or method.

Such modifications may affect sterility assurance, material properties, packaging integrity, and product performance.

Manufacturers should establish appropriate validation and supporting evidence before submitting the change for regulatory review.

2.5 Change in Approved Shelf Life

Any modification to the approved shelf life of a medical device is classified as a major change.

Examples include:

• Extending shelf life from two years to three years.
• Reducing the approved shelf life based on new stability findings.
• Revising the expiry period following changes in materials or packaging.

The manufacturer should support the proposed shelf-life change with appropriate stability data, packaging studies, and other relevant evidence.

A shelf-life extension should never be implemented merely on the basis of internal assumptions or commercial requirements.

2.6 Change in Manufacturer or Manufacturing Site Details

Changes to the name or address of specified manufacturing entities are included in the major-change category.

This includes changes relating to:

• Domestic manufacturer name or address.
• Domestic manufacturing site name or address.
• Overseas manufacturer name or address, for imported devices.
• Overseas manufacturing site name or address, for imported devices.
• Authorised agent name or address, for imported devices.

For example, when a manufacturer relocates production from one approved facility to another, the change must be assessed and submitted through the applicable post-approval change process.

CDSCO's November 2025 FAQ addendum also clarifies that a change in the actual manufacturing site name, without a change in constitution, requires approval through a Post Approval Change application.

It further clarifies that relocation of an Indian manufacturing site requires a QMS re-inspection/audit.

2.7 Changes in Medical Device Labelling

Changes to approved labelling particulars are generally considered major changes.

Examples include:

• Modifying important product information.
• Changing approved warnings or precautions.
• Revising the device's approved intended-use statement on the label.
• Changing critical safety information.

However, the Sixth Schedule excludes changes limited to font size, font type, colour, and label design from this major-change category.

Manufacturers must still ensure that revised labels comply with applicable labelling requirements and do not introduce misleading or inconsistent information.

2.8 Changes in Manufacturing Process, Equipment or Testing

A modification to the manufacturing process, production equipment, or testing procedures is considered major when it affects the quality of the medical device.

Examples include:

• Introducing a different manufacturing technology.
• Changing a critical production parameter.
• Replacing important manufacturing equipment where product quality is affected.
• Changing a critical quality-control testing method.
• Modifying a process that affects the device's mechanical or functional properties.

The manufacturer should conduct an appropriate impact assessment, process validation, and verification before submitting the proposed change.

2.9 Change in Primary Packaging Material

A change in the primary packaging material is also considered a major change under the Sixth Schedule.

Examples include:

• Replacing the approved blister packaging material.
• Changing the material of a sterile barrier system.
• Replacing the primary packaging used for a sterile medical device.
• Changing packaging material that may affect product stability or integrity.

Primary packaging plays an important role in protecting medical devices from contamination, environmental exposure, and physical damage.

Therefore, such changes require regulatory assessment and prior approval.

3. Which Medical Device Changes Are Generally Considered Minor Changes?

Not every product modification requires prior approval. Certain changes may be classified as minor when they do not affect the quality, safety, performance, specifications, indications for use, or stability of the approved device.

Under Part B of the Sixth Schedule, the following are identified as minor changes:

Important: Minor changes are subject to notification to the concerned Licensing Authority. They should not be treated as changes that can be made without regulatory documentation or notification.

The manufacturer should maintain an appropriate technical justification demonstrating why the change does not affect the approved device's quality or performance.

Examples of minor changes

• Changing secondary packaging dimensions without affecting primary packaging.
• Modifying a non-critical manufacturing process parameter without affecting product quality.
• Updating equipment that performs a non-critical manufacturing operation.
• Making a design adjustment that does not affect approved specifications or performance.

The actual classification must always be based on the applicable regulatory provisions and documented evidence.

4. Special Considerations for Medical Device Software Changes

With increasing use of digital health technologies, software modifications have become an important part of medical device regulatory compliance.

CDSCO issued its final Guidance Document on Medical Device Software under MDR-2017 on 21 July 2026, providing additional clarity on software-related regulatory requirements and post-approval changes.

According to this guidance, the following software modifications may require prior regulatory approval:

• Changes to software design characteristics that affect quality or performance.
• Changes in software system requirements.
• Introduction of new clinical claims.
• Addition of new data input types.
• Changes to intended use or indications for use.
• Software version changes affecting safety, effectiveness, or risk-control measures.
• Changes to manufacturing or testing processes that affect device quality.

On the other hand, certain changes may be considered minor and require notification, including:

• Bug fixes that do not affect intended use, safety, or performance.
• Security patches without an impact on intended use, safety, or performance.
• Software version updates that do not affect safety or effectiveness.
• Performance retuning within validated ranges.

The guidance also requires suitable software change management, version control, traceability, and documentation.

This is particularly important for AI/ML-enabled medical devices, where software modifications and algorithm updates may influence clinical performance and patient safety.

5. How Should Manufacturers Apply for Post-Approval Changes?

Manufacturers and importers should follow a structured regulatory procedure before implementing a proposed modification.

CDSCO's FAQ Addendum No. 03, dated 3 November 2025, clarifies that changes to a licensed device or manufacturing site require submission of a Post Approval Change (PAC) application to the concerned Licensing Authority through the Online System for Medical Devices.

The recommended regulatory workflow is as follows:

Post-Approval Change Management Workflow

1. Identify the proposed change

Document the reason, scope, and technical details of the proposed modification.

2. Conduct an impact assessment

Evaluate its potential impact on product quality, safety, performance, stability, and intended use.

3. Classify the change

Determine whether the proposed modification is major or minor under the Sixth Schedule.

4. Prepare supporting documentation

Compile technical justifications, validation reports, risk assessments, test results, and revised documents, as applicable.

5. Submit the PAC application

Submit the appropriate application through the CDSCO Online System for Medical Devices to the concerned CLA or SLA.

6. Obtain approval or complete notification requirements

Obtain prior approval for major changes. For minor changes, complete the applicable notification requirements.

7. Implement and maintain records

Implement the change in accordance with the applicable regulatory requirements and update internal quality and technical documentation.

Important regulatory distinction: A major change must not be implemented before the required approval is obtained. A minor change must follow the applicable notification process. Submission of an application alone should not be considered regulatory approval.

6. Documents Required for a Medical Device Post-Approval Change Application

The supporting documentation depends on the nature of the proposed change, the device category, and the Licensing Authority's requirements.

Manufacturers should generally evaluate the need for the following documents:

Not every document is mandatory for every PAC application. The submission should be tailored to the specific change and applicable CDSCO requirements.

7. Common Regulatory Mistakes Manufacturers Should Avoid

Even well-established medical device manufacturers can face compliance difficulties because of inadequate post-approval change management.

Some common mistakes include:

1. Implementing major changes before approval

Introducing a modification to an approved product without obtaining the required regulatory approval can result in non-compliance.

2. Treating every modification as a minor change

A change that appears technically small may affect device performance, safety, or intended use.

3. Ignoring manufacturing site modifications

Changes in manufacturing site details should be evaluated and submitted through the applicable PAC pathway.

4. Failing to maintain technical evidence

Manufacturers should maintain documented justifications, validation reports, and risk assessments supporting every relevant change.

5. Overlooking software updates

Changes to software functionality, clinical claims, algorithms, and performance must be evaluated under the applicable medical device software requirements.

6. Updating labels without regulatory assessment

Changes to approved labelling particulars must be reviewed carefully, particularly when they affect intended use, safety information, or product claims.

8. Frequently Asked Questions (FAQs)

Q1. Which medical device changes require prior CDSCO approval?

Changes in material of construction, critical design characteristics, intended use, sterilisation method, approved shelf life, manufacturer or manufacturing site details, specified labelling particulars, quality-affecting manufacturing processes, and primary packaging material are classified as major changes under the Sixth Schedule of MDR, 2017.

Q2. Can a manufacturer change the packaging of an approved medical device without prior approval?

It depends on the type of packaging. Changes to primary packaging material are major changes requiring prior approval. Certain changes in packaging specifications, excluding primary packaging material, are classified as minor changes and require notification.

Q3. Does a change in the manufacturing site require CDSCO approval?

Yes. Changes involving the name or address of the manufacturing site fall under the major-change category and require the applicable prior approval.

Q4. Are software updates considered major changes?

Not necessarily. Software updates affecting intended use, safety, effectiveness, clinical claims, or risk-control measures may be major changes. Certain bug fixes, security patches, and version updates that do not affect these aspects may be minor changes.

Q5. Does a change in the intended use require prior approval?

Yes. A change or expansion of approved intended use or indications for use is considered a major change requiring prior regulatory approval.

Q6. Where should manufacturers submit post-approval change applications?

Applications should be submitted through the CDSCO Online System for Medical Devices to the concerned Central Licensing Authority or State Licensing Authority, depending on the applicable licence and regulatory jurisdiction.

Q7. Can a manufacturer implement a major change while the application is under review?

No. The major change must not be implemented before the required regulatory approval is obtained.

9. Conclusion

Post-approval change management is an essential part of medical device regulatory compliance in India. Under the Medical Devices Rules, 2017, manufacturers and importers must carefully assess modifications to their approved products, manufacturing processes, packaging, labelling, and manufacturing facilities.

The Sixth Schedule provides the regulatory distinction between major and minor changes. While major changes require prior approval, minor changes are subject to the applicable notification requirements.

With the growing adoption of advanced medical technologies, software-based devices, and AI-enabled healthcare solutions, manufacturers must also pay close attention to the additional expectations outlined in CDSCO's 2026 Medical Device Software Guidance.

A well-defined change control procedure, supported by appropriate technical documentation, risk assessment, and regulatory review, helps manufacturers maintain compliance while ensuring the continued quality, safety, and performance of medical devices.

The key takeaway: Evaluate every proposed change before implementation, determine its regulatory classification, and complete the applicable CDSCO requirements.

Last Updated : 02 Nov 2026